Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy
Clinical Trials
Related News

Aripiprazole in Late Life Bipolar Disorder

Phase 4
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Aripiprazole
First Posted Date
2005-09-19
Last Posted Date
2014-12-17
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
20
Registration Number
NCT00194038

Study of Aripiprazole (Abilify) in Children With Symptoms of Mania

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Placebo
Drug: Aripiprazole
First Posted Date
2005-09-19
Last Posted Date
2015-01-07
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
60
Registration Number
NCT00194077
Locations
🇺🇸

University Hospitals Case Medical Center, Cleveland, Ohio, United States

Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

First Posted Date
2005-09-15
Last Posted Date
2007-01-29
Lead Sponsor
University of Medicine and Dentistry of New Jersey
Target Recruit Count
18
Registration Number
NCT00177008
Locations
🇺🇸

Robert Wood Johnson Medical School - Psychiatry Dept., Piscataway, New Jersey, United States

Aripiprazole Treatment of the Prodrome

Not Applicable
Terminated
Conditions
Prodromal Schizophrenia
Prodromal Psychosis
First Posted Date
2005-09-15
Last Posted Date
2009-09-25
Lead Sponsor
Northwell Health
Target Recruit Count
30
Registration Number
NCT00169949
Locations
🇺🇸

RAP Program, Dept. of Psychiatry Research, The Zucker Hillside Hospital, Glen Oaks, New York, United States

Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2005-09-14
Last Posted Date
2007-04-19
Lead Sponsor
Veterans Medical Research Foundation
Target Recruit Count
15
Registration Number
NCT00167817
Locations
🇺🇸

VA San Diego Healthcare System, San Diego, California, United States

Aripiprazole in Children and Adolescents With Bipolar Disorder and Attention Deficit Hyperactivity Disorder (ADHD)

First Posted Date
2005-06-28
Last Posted Date
2008-08-07
Lead Sponsor
Federal University of Rio Grande do Sul
Target Recruit Count
50
Registration Number
NCT00116259
Locations
🇧🇷

ADHD outpatient program, Porto Alegre - Brazil, RS, Brazil

Aripiprazole in Children and Adolescents With Bipolar I Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
Drug: placebo
Drug: Aripiprazole
First Posted Date
2005-05-10
Last Posted Date
2012-05-21
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
296
Registration Number
NCT00110461
Locations
🇺🇸

Local Institution, Milwaukee, Wisconsin, United States

Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2005-02-11
Last Posted Date
2007-11-06
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
600
Registration Number
NCT00103571
Locations
🇵🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. test, Rio Piedras, Puerto Rico

Aripiprazole Pharmacokinetics (PK) and Tolerability Study in Children and Adolescents

Phase 2
Completed
Conditions
Schizophrenia
Mania
First Posted Date
2005-01-31
Last Posted Date
2006-04-17
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Registration Number
NCT00102479

Aripiprazole Open-Label, Safety and Tolerability Study

Phase 3
Completed
Conditions
Schizophrenia
Bipolar Disorder
Interventions
Drug: Aripiprazole
First Posted Date
2005-01-31
Last Posted Date
2012-08-31
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Target Recruit Count
325
Registration Number
NCT00102518
Locations
🇺🇸

Local Institution, Wauwatosa, Wisconsin, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy